| 4.29 -0.12 (-2.72%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.33 | 1-year : | 7.35 |
| Resists | First : | 5.42 | Second : | 6.3 |
| Pivot price | 4.49 |
|||
| Supports | First : | 4 | Second : | 3.32 |
| MAs | MA(5) : | 4.56 |
MA(20) : | 4.47 |
| MA(100) : | 5.96 |
MA(250) : | 7.24 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2  |
| %K %D | K(14,3) : | 30.6 |
D(3) : | 53.9 |
| RSI | RSI(14): 40.9 |
|||
| 52-week | High : | 11.89 | Low : | 4 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SABS ] has closed above bottom band by 14.5%. Bollinger Bands are 62.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.31 - 4.35 | 4.35 - 4.37 |
| Low: | 4.22 - 4.26 | 4.26 - 4.28 |
| Close: | 4.24 - 4.3 | 4.3 - 4.34 |
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
Tue, 16 Apr 2024
SAB Biotherapeutics Provides SAB-142 Trial Update - Yahoo Finance
Mon, 08 Apr 2024
SAB Biotherapeutics to Present at INNODIA Annual Meeting - Yahoo Finance
Thu, 04 Apr 2024
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference - Yahoo Finance
Mon, 01 Apr 2024
SAB Biotherapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
Fri, 29 Mar 2024
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results - GlobeNewswire
Wed, 14 Feb 2024
SAB Biotherapeutics announces new CEO - SiouxFalls.Business - SiouxFalls.Business
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 5.93e+006 (%) |
| Held by Institutions | 19.1 (%) |
| Shares Short | 25 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.442e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -6 % |
| Return on Assets (ttm) | 187.8 % |
| Return on Equity (ttm) | -35.3 % |
| Qtrly Rev. Growth | 2.24e+006 % |
| Gross Profit (p.s.) | -107.38 |
| Sales Per Share | -119.39 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -7.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.04 |
| Price to Cash Flow | 0.55 |
| Dividend | 0 |
| Forward Dividend | 28860 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|